These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
429 related articles for article (PubMed ID: 23598551)
21. The nutraceutical potential of Lepidium sativum L. seed flavonoid-rich extract in managing metabolic syndrome components. L'hadj I; Azzi R; Lahfa F; Koceir EA; Omari N J Food Biochem; 2019 Mar; 43(3):e12725. PubMed ID: 31353542 [TBL] [Abstract][Full Text] [Related]
22. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Sun L; Cai J; Gonzalez FJ Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795 [TBL] [Abstract][Full Text] [Related]
23. PPAR ligands for metabolic disorders. Etgen GJ; Mantlo N Curr Top Med Chem; 2003; 3(14):1649-61. PubMed ID: 14683520 [TBL] [Abstract][Full Text] [Related]
24. Microbial Flavonoid Metabolism: A Cardiometabolic Disease Perspective. Osborn LJ; Claesen J; Brown JM Annu Rev Nutr; 2021 Oct; 41():433-454. PubMed ID: 34633856 [TBL] [Abstract][Full Text] [Related]
25. Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy. Tobin JF; Freedman LP Trends Endocrinol Metab; 2006 Sep; 17(7):284-90. PubMed ID: 16870465 [TBL] [Abstract][Full Text] [Related]
26. Splice variants of metabolic nuclear receptors: Relevance for metabolic disease and therapeutic targeting. Mukha A; Kalkhoven E; van Mil SWC Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166183. PubMed ID: 34058349 [TBL] [Abstract][Full Text] [Related]
27. Impact of Red Yeast Rice on Metabolic Diseases: A Review of Possible Mechanisms of Action. Hu J; Wang J; Gan QX; Ran Q; Lou GH; Xiong HJ; Peng CY; Sun JL; Yao RC; Huang QW J Agric Food Chem; 2020 Sep; 68(39):10441-10455. PubMed ID: 32854499 [TBL] [Abstract][Full Text] [Related]
28. Nuclear receptor coregulators as a new paradigm for therapeutic targeting. Hsia EY; Goodson ML; Zou JX; Privalsky ML; Chen HW Adv Drug Deliv Rev; 2010 Oct; 62(13):1227-37. PubMed ID: 20933027 [TBL] [Abstract][Full Text] [Related]
29. Dietary Flavonoids and Insulin Signaling in Diabetes and Obesity. Martín MÁ; Ramos S Cells; 2021 Jun; 10(6):. PubMed ID: 34208379 [TBL] [Abstract][Full Text] [Related]
30. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Calkin AC; Tontonoz P Nat Rev Mol Cell Biol; 2012 Mar; 13(4):213-24. PubMed ID: 22414897 [TBL] [Abstract][Full Text] [Related]
31. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. Halilbasic E; Fuchs C; Traussnigg S; Trauner M Dig Dis; 2016; 34(5):580-8. PubMed ID: 27332721 [TBL] [Abstract][Full Text] [Related]
35. Quantitative determination of phenolic compounds in artichoke-based dietary supplements and pharmaceuticals by high-performance liquid chromatography. Schütz K; Muks E; Carle R; Schieber A J Agric Food Chem; 2006 Nov; 54(23):8812-7. PubMed ID: 17090127 [TBL] [Abstract][Full Text] [Related]
36. PPARs as targets for metabolic and cardiovascular diseases. Cheng PT; Mukherjee R Mini Rev Med Chem; 2005 Aug; 5(8):741-53. PubMed ID: 16101410 [TBL] [Abstract][Full Text] [Related]
37. Long-Term Dietary Supplementation with Yerba Mate Ameliorates Diet-Induced Obesity and Metabolic Disorders in Mice by Regulating Energy Expenditure and Lipid Metabolism. Choi MS; Park HJ; Kim SR; Kim DY; Jung UJ J Med Food; 2017 Dec; 20(12):1168-1175. PubMed ID: 28872427 [TBL] [Abstract][Full Text] [Related]
38. Targeting farnesoid X receptor for liver and metabolic disorders. Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816 [TBL] [Abstract][Full Text] [Related]
39. Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. Mosialou I; Zannis VI; Kardassis D J Biol Chem; 2010 Oct; 285(40):30719-30. PubMed ID: 20660599 [TBL] [Abstract][Full Text] [Related]